Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

• Main Authors: Se Yong Jung (Author), Min Seo Kim (Author), Han Li (Author), Keum Hwa Lee (Author), Ai Koyanagi (Author), Marco Solmi (Author), Andreas Kronbichler (Author), Elena Dragioti (Author), Kalthoum Tizaoui (Author), Sarah Cargnin (Author), Salvatore Terrazzino (Author), Sung Hwi Hong (Author), Ramy Abou Ghayda (Author), Nam Kyun Kim (Author), Seo Kyoung Chung (Author), Louis Jacob (Author), Joe‐Elie Salem (Author), Dong Keon Yon (Author), Seung Won Lee (Author), Karel Kostev (Author), Ah Young Kim (Author), Jo Won Jung (Author), Jae Young Choi (Author), Jin Soo Shin (Author), Soon‐Jung Park (Author), Seong Woo Choi (Author), Kiwon Ban (Author), Sung‐Hwan Moon (Author), Yun Young Go (Author), Jae Il Shin (Author), Lee Smith (Author)
• Formato: Libro
• Publicado: Wiley, 2022-02-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Abstract On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unkno...